Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients

Ruben Bellotti; Salvatore Paiella; Florian Primavesi; Carsten Jäger; Ihsan E Demir; Fabio Casciani; Peter Kornprat; Doris Wagner; Christiane S Rösch; Giovanni Butturini; Alessandro Giardino; Peter Goretzki; Martina Mogl; Tim Fahlbusch; Jörg Kaiser; Oliver Strobel; Anna Nießen; Andreas M Luu; Roberto Salvia; Manuel Maglione

doi:10.1016/j.hpb.2023.07.897

Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients

Standard

Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients. / Bellotti, Ruben; Paiella, Salvatore; Primavesi, Florian; Jäger, Carsten; Demir, Ihsan E; Casciani, Fabio; Kornprat, Peter; Wagner, Doris; Rösch, Christiane S; Butturini, Giovanni; Giardino, Alessandro; Goretzki, Peter; Mogl, Martina; Fahlbusch, Tim; Kaiser, Jörg; Strobel, Oliver; Nießen, Anna; Luu, Andreas M; Salvia, Roberto; Maglione, Manuel.

In: HPB, Vol. 25, No. 11, 11.2023, p. 1411-1419.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bellotti, R, Paiella, S, Primavesi, F, Jäger, C, Demir, IE, Casciani, F, Kornprat, P, Wagner, D, Rösch, CS, Butturini, G, Giardino, A, Goretzki, P, Mogl, M, Fahlbusch, T, Kaiser, J, Strobel, O, Nießen, A, Luu, AM, Salvia, R & Maglione, M 2023, 'Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients', HPB, vol. 25, no. 11, pp. 1411-1419. https://doi.org/10.1016/j.hpb.2023.07.897

APA

Bellotti, R., Paiella, S., Primavesi, F., Jäger, C., Demir, I. E., Casciani, F., Kornprat, P., Wagner, D., Rösch, C. S., Butturini, G., Giardino, A., Goretzki, P., Mogl, M., Fahlbusch, T., Kaiser, J., Strobel, O., Nießen, A., Luu, A. M., Salvia, R., & Maglione, M. (2023). Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients. HPB, 25(11), 1411-1419. https://doi.org/10.1016/j.hpb.2023.07.897

Vancouver

Bellotti R, Paiella S, Primavesi F, Jäger C, Demir IE, Casciani F et al. Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients. HPB. 2023 Nov;25(11):1411-1419. https://doi.org/10.1016/j.hpb.2023.07.897

Bibtex

@article{1282ae4e83b346c58c4c2208937f7a3f,

title = "Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients",

abstract = "BACKGROUND: Acinar cell carcinomas (ACC) belong to the exocrine pancreatic malignancies. Due to their rarity, there is no consensus regarding treatment strategies for resectable ACC.METHODS: This is a retrospective multicentric study of radically resected pure pancreatic ACC. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Further endpoints were oncologic outcomes related to tumor stage and therapeutic protocols.RESULTS: 59 patients (44 men) with a median age of 64 years were included. The median tumor size was 45.0 mm. 61.0% were pT3 (n = 36), nodal positivity rate was 37.3% (n = 22), and synchronous distant metastases were present in 10.1% of the patients (n = 6). 5-Years OS was 60.9% and median DFS 30 months. 24 out of 31 recurred systemically (n = 18 only systemic, n = 6 local and systemic). Regarding TNM-staging, only the N2-stage negatively influenced OS and DFS (p = 0.004, p = 0.001). Adjuvant treatment protocols (performed in 62.7%) did neither improve OS (p = 0.542) nor DFS (p = 0.159). In 9 cases, radical resection was achieved following neoadjuvant therapy.DISCUSSION: Radical surgery is currently the mainstay for resectable ACC, even for limited metastatic disease. Novel (neo)adjuvant treatment strategies are needed, since current systemic therapies do not result in a clear survival benefit in the perioperative setting.",

author = "Ruben Bellotti and Salvatore Paiella and Florian Primavesi and Carsten J{\"a}ger and Demir, {Ihsan E} and Fabio Casciani and Peter Kornprat and Doris Wagner and R{\"o}sch, {Christiane S} and Giovanni Butturini and Alessandro Giardino and Peter Goretzki and Martina Mogl and Tim Fahlbusch and J{\"o}rg Kaiser and Oliver Strobel and Anna Nie{\ss}en and Luu, {Andreas M} and Roberto Salvia and Manuel Maglione",

year = "2023",

month = nov,

doi = "10.1016/j.hpb.2023.07.897",

language = "English",

volume = "25",

pages = "1411--1419",

journal = "HPB",

issn = "1365-182X",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

RIS

TY - JOUR

T1 - Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas - A multicentric European study on radically resected patients

AU - Bellotti, Ruben

AU - Paiella, Salvatore

AU - Primavesi, Florian

AU - Jäger, Carsten

AU - Demir, Ihsan E

AU - Casciani, Fabio

AU - Kornprat, Peter

AU - Wagner, Doris

AU - Rösch, Christiane S

AU - Butturini, Giovanni

AU - Giardino, Alessandro

AU - Goretzki, Peter

AU - Mogl, Martina

AU - Fahlbusch, Tim

AU - Kaiser, Jörg

AU - Strobel, Oliver

AU - Nießen, Anna

AU - Luu, Andreas M

AU - Salvia, Roberto

AU - Maglione, Manuel

PY - 2023/11

Y1 - 2023/11

N2 - BACKGROUND: Acinar cell carcinomas (ACC) belong to the exocrine pancreatic malignancies. Due to their rarity, there is no consensus regarding treatment strategies for resectable ACC.METHODS: This is a retrospective multicentric study of radically resected pure pancreatic ACC. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Further endpoints were oncologic outcomes related to tumor stage and therapeutic protocols.RESULTS: 59 patients (44 men) with a median age of 64 years were included. The median tumor size was 45.0 mm. 61.0% were pT3 (n = 36), nodal positivity rate was 37.3% (n = 22), and synchronous distant metastases were present in 10.1% of the patients (n = 6). 5-Years OS was 60.9% and median DFS 30 months. 24 out of 31 recurred systemically (n = 18 only systemic, n = 6 local and systemic). Regarding TNM-staging, only the N2-stage negatively influenced OS and DFS (p = 0.004, p = 0.001). Adjuvant treatment protocols (performed in 62.7%) did neither improve OS (p = 0.542) nor DFS (p = 0.159). In 9 cases, radical resection was achieved following neoadjuvant therapy.DISCUSSION: Radical surgery is currently the mainstay for resectable ACC, even for limited metastatic disease. Novel (neo)adjuvant treatment strategies are needed, since current systemic therapies do not result in a clear survival benefit in the perioperative setting.

AB - BACKGROUND: Acinar cell carcinomas (ACC) belong to the exocrine pancreatic malignancies. Due to their rarity, there is no consensus regarding treatment strategies for resectable ACC.METHODS: This is a retrospective multicentric study of radically resected pure pancreatic ACC. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Further endpoints were oncologic outcomes related to tumor stage and therapeutic protocols.RESULTS: 59 patients (44 men) with a median age of 64 years were included. The median tumor size was 45.0 mm. 61.0% were pT3 (n = 36), nodal positivity rate was 37.3% (n = 22), and synchronous distant metastases were present in 10.1% of the patients (n = 6). 5-Years OS was 60.9% and median DFS 30 months. 24 out of 31 recurred systemically (n = 18 only systemic, n = 6 local and systemic). Regarding TNM-staging, only the N2-stage negatively influenced OS and DFS (p = 0.004, p = 0.001). Adjuvant treatment protocols (performed in 62.7%) did neither improve OS (p = 0.542) nor DFS (p = 0.159). In 9 cases, radical resection was achieved following neoadjuvant therapy.DISCUSSION: Radical surgery is currently the mainstay for resectable ACC, even for limited metastatic disease. Novel (neo)adjuvant treatment strategies are needed, since current systemic therapies do not result in a clear survival benefit in the perioperative setting.

U2 - 10.1016/j.hpb.2023.07.897

DO - 10.1016/j.hpb.2023.07.897

M3 - SCORING: Journal article

C2 - 37563033

VL - 25

SP - 1411

EP - 1419

JO - HPB

JF - HPB

SN - 1365-182X

IS - 11

ER -